Theralink Technologies and VieCure Announce Strategic Agreement

DENVER, Colorado — July 8th, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP), a
molecular profiling company specializing in biomarker assay services that target multiple areas of oncology,
announced today the signing of a multi-year strategic agreement with VieCure™ to enhance personalized
cancer treatment in community oncology settings.

Theralink Technologies will provide VieCure™ platform users, including Medical Oncologists, with a new and
powerful source of precision medicine through dissemination and proper use of its Theralink assay. Theralink
is a leading developer of phosphoproteomic technology that can measure the activation state of key cancer
drug targets and signaling pathways within a microscopic quantity of a breast cancer tumor sample.
Measuring the direct activation state for (or response to) dozens of drug targets at once provides oncologists
with key information about the patient’s specific tumor. VieCure has developed a state-of-the-art artificial
intelligence platform which combines a smart oncology eMR with the latest clinical guidance (including clinical
trials) in the form of codified rules and algorithms. The VieCure™ platform will match relevant patients to
the Theralink observational registry clinical trial (known as TRACE) beginning this summer.

The initial use for the TheraLink® assay is for Breast Cancer patients who present with:
• Late stage (stage III-IV) Triple Negative Breast Cancer
• Any stage Inflammatory Breast Cancer
• Metastatic Breast Cancer
• Late stage (stage III-IV) ER+/HER2- Breast Cancer
Electronic interfaces between the VieCure™ platform and the Theralink Lockbox Laboratory Information
Management System (LIMS) will be developed and will facilitate the digital exchange of patient data for
tumor profiling and Theralink assay results reporting.

“We will be launching our patented, proteomic-based Theralink® assay initially for breast cancer patients,
and then planned for most solid tumors, through a prospective, observational registration trial to a select
group of oncologists,” said Mick Ruxin, M.D. President and CEO of Theralink Technologies, Inc. “We are very
pleased that through our partnership with VieCure, their physician network will have preferred access to the
next generation of testing for cancer patients, extending VieCure™ Platform’s genomics information to now
include phosphoprotein and protein based information.”

Dr. Joyce O’Shaughnessy, a practicing Medical Oncologist at Texas Oncology, said, “The Theralink assay
allows me to understand which protein biomarkers and signaling pathways are active and driving my
patient’s metastatic breast cancer growth. Proteomic information can be instrumental in helping guide
therapy choices for my patients.”

“The real time information gathered by the oncologist through the use of the Theralink assay and the VieCure

smart eMR has the potential to both increase the frequency of actionable findings as well as help physicians
make better and more rationalized treatment decisions that can improve treatment outcomes and reduce
side effects by foregoing ineffective therapies,” said Dr. Fred Ashbury, Chief Scientific Officer at VieCure.

VieCure will also codify Theralink TRACE clinical protocols within their platform. These algorithms will trigger
the participating oncologist to consider putting the relevant breast cancer patient on the Theralink trial where
the clinical rules indicate benefit.

The initial term of the agreement is for 5 years with opportunities for renewal and the addition of other
disease sites, assays and indications.

About VieCure

VieCure has developed the proprietary VieCure platform (the “Platform”), a real-time decision-support
system that combines clinical knowledge with patient data to assist oncologists in generating personalized
treatment plans and managing a patient’s care throughout his or her cancer therapy. The Platform
encompasses a proprietary artificial intelligence engine, a knowledge base containing world-leading
precision medicine and standard of care guidance and an integrated electronic medical record, specifically
created for oncology practices. The platform allows the treatment team to select a preferred course of
therapy from a database of treatment plans and modify it as appropriate for the individual patient’s unique
circumstances, following best practices including precision medicine options where indicated, as well as
institution-specific clinical and financial rules and guidance. Throughout the continuum of care, the platform’s
rules-based algorithms suggest therapy adjustments for the treatment team to consider, based on the
patient’s test results (including next generation tumor sequencing and proteomics) and specific responses to
treatment. The Platform’s embedded eMR functionality includes registration and demographics, scheduling,

evaluation and management, toxicity tracking and management, performance status monitoring, orders,
pharmacy dispensing, medication administration record, charge capture, progress notes, and flowsheet. It
also has a tethered mobile patient app to assist with streamlining communication between providers and

About Theralink Technologies, Inc.

Theralink Technologies is a molecular profiling company, located in Golden, Colorado that specializes in
biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data
through its Theralink® assays to assist the biopharmaceutical industry and clinical oncologists in identifying
likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend
to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support
biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling. For
more information, please visit

Contact Information
Theralink Technologies, Inc.
KCSA Strategic Communications
Valter Pinto, Managing Director

Katherine Gresh
Client Manager and Marketing Coordinator

Forward-Looking Statements

Certain statements contained in this press release are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including, without limitation, anything relating or

referring to future financial results, patient enrollment and plans for future business development activities,
and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some
of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties
include, without limitation, the risks and uncertainties set forth from time to time in reports filed by
OncBioMune Pharmaceuticals with the Securities and Exchange Commission. We have based these forward-
looking statements largely on our current expectations and projections about future events and financial
trends affecting the financial condition of our business and although the company believes that the
expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such
expectations will prove to have been correct. Consequently, future events and actual results could differ
materially from those set forth in, contemplated by, or underlying the forward the forward-looking
statements contained herein. The company undertakes no obligation to publicly release statements made to
reflect events or circumstances after the date hereof.